This promotional message is being sent to you on behalf of Aerie Pharmaceuticals, Inc.
Can’t see this? |  View it online
IOP control, customized for your patients’ needs.
Each of your glaucoma patients has unique treatment needs—some may need significant IOP reduction from the very beginning, while others may need additional IOP reduction. That’s where Rocklatan® and Rhopressa® come in.
A simple replacement can advance IOP reduction
Replacing your patient’s current PGA with once daily Rocklatan® could offer advancing IOP reduction in a single bottle for your patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).1,2
In a 12-month clinical trial of patients with OAG and OHT, Rocklatan® offered superior IOP reduction compared to latanoprost.3 And with one drop, once-daily, you could lessen the treatment burden and improve compliance for your patients.4
Netarsudil was specifically designed to target the trabecular meshwork to increase aqueous humor outflow1, while also decreasing episcleral venous pressure (EVP).5
Questions about tolerability? The majority of ocular adverse events were mild and tolerable.1,6
Please see below for Important Safety Information.
Add one drop for additional IOP reduction
Adding Rhopressa® to your patients’ treatment plan could help achieve additional IOP reduction.7 That means adding treatment versatility for more glaucoma patients.
Rhopressa® is a first-of-its-kind ROCK inhibitor that lowers IOP in patients with OAG or OHT by targeting the trabecular meshwork to increase aqueous humor outflow,7 and by decreasing episcleral venous pressure.5
Rhopressa® delivers consistent IOP reduction of ~20% whether adding Rhopressa® to a PGA monotherapy or to a combination of therapies.6
Please see below for Important Safety Information.
Learn more about how Rocklatan® and Rhopressa® can help your glaucoma patients’ meet their treatment goals
ROCKLATAN® IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
•
Pigmentation changes
•
Eyelash changes
•
Intraocular inflammation
•
Macular edema
•
Herpetic keratitis
•
Bacterial keratitis
•
Contact lens wear
Adverse reactions
Rocklatan®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.
Netarsudil 0.02%: Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid.
Latanoprost 0.005%: Foreign body sensation, punctate keratitis, burning and stinging, itching, increased pigmentation of the iris, excessive tearing, eyelid discomfort, dry eye, eye pain, eyelid margin crusting, erythema of the eyelid, upper respiratory tract infection/nasopharyngitis/influenza, photophobia, eyelid edema, myalgia/arthralgia/back pain, and rash/allergic reaction.
Please visit Rocklatan.com for full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
INDICATION
Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
RHOPRESSA® IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.
Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.
ADVERSE REACTIONS
The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.
The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.
Please visit Rhopressa.com for full prescribing information for Rhopressa®.
You are encouraged to report negative side effects of prescription drugs to the FDA.
INDICATION
Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening.
References:
1.
Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2020.
2.
Asrani S, Robin A, Serle J, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019; 207: 248-257.
3.
Brubaker J, Teymoorian S, Lewis R, et al. Once-daily fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension/open-angle glaucoma: 12-month data from MERCURY-1. Presented at the 28th Meeting of the American Glaucoma Society, March 2018.
4.
Prum B Jr, Rosenberg L, Gedde S, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines. Ophthalmology. 2016;123(1):P41-P111.
5.
Kazemi A, McLaren JW, Kopczynski CC, et al. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34(5):380-386.
6.
Data on file, Aerie Pharmaceuticals, Inc., Irvine, Calif.
7.
Rhopressa® (netarsudil ophthalmic solution) 0.02% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.
To unsubscribe from this program, click here.
Please do not reply to this email. This mailbox is not monitored.
©2020 Aerie Pharmaceuticals, Inc. All rights reserved.
US-RHO-P-0209 C